FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080943490> ?p ?o ?g. }

• W2080943490 endingPage "2113" @default.
• W2080943490 startingPage "2104" @default.
• W2080943490 abstract "Abstract The prognosis of ovarian cancer, the primary cause of death from gynecological malignancies, has only modestly improved over the last decades. Immunotherapy is one of the new treatment modalities explored for this disease. To investigate safety, tolerability, immunogenicity and obtain an impression of clinical activity of a p53 synthetic long peptide (p53‐SLP) vaccine, twenty patients with recurrent elevation of CA‐125 were included, eighteen of whom were immunized 4 times with 10 overlapping p53‐SLP in Montanide ISA51. The first 5 patients were extensively monitored for toxicity, but showed no ≥ grade 3 toxicity, thus accrual was continued. Overall, toxicity was limited to grade 1 and 2, mostly locoregional, inflammatory reactions. IFN‐γ producing p53‐specific T‐cell responses were induced in all patients who received all 4 immunizations as measured by IFN‐γ ELISPOT. An IFN‐γ secretion assay showed that vaccine‐induced p53‐specific T‐cells were CD4 + , produced both Th1 and Th2 cytokines as analyzed by cytokine bead array. Notably, Th2 cytokines dominated the p53‐specific response. P53‐specific T‐cells were present in a biopsy of the last immunization site of at least 9/17 (53%) patients, reflecting the migratory capacity of p53‐specific T‐cells. As best clinical response, stable disease evaluated by CA‐125 levels and CT‐scans, was observed in 2/20 (10%) patients, but no relationship was found with vaccine‐induced immunity. This study shows that the p53‐SLP vaccine is safe, well tolerated and induces p53‐specific T‐cell responses in ovarian cancer patients. Upcoming trials will focus on improving T helper‐1 polarization and clinical efficacy. © 2009 UICC" @default.
• W2080943490 created "2016-06-24" @default.
• W2080943490 creator A5004316854 @default.
• W2080943490 creator A5009928901 @default.
• W2080943490 creator A5012460959 @default.
• W2080943490 creator A5015085014 @default.
• W2080943490 creator A5018392015 @default.
• W2080943490 creator A5020466822 @default.
• W2080943490 creator A5021731198 @default.
• W2080943490 creator A5023772387 @default.
• W2080943490 creator A5029794143 @default.
• W2080943490 creator A5036607864 @default.
• W2080943490 creator A5038242415 @default.
• W2080943490 creator A5041281028 @default.
• W2080943490 creator A5042340711 @default.
• W2080943490 creator A5068364166 @default.
• W2080943490 creator A5074386778 @default.
• W2080943490 creator A5078581728 @default.
• W2080943490 creator A5082166656 @default.
• W2080943490 creator A5089369970 @default.
• W2080943490 creator A5089778955 @default.
• W2080943490 creator A5090541124 @default.
• W2080943490 date "2009-07-20" @default.
• W2080943490 modified "2023-10-17" @default.
• W2080943490 title "Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial" @default.
• W2080943490 cites W1444462873 @default.
• W2080943490 cites W1481535764 @default.
• W2080943490 cites W1522781268 @default.
• W2080943490 cites W1541202713 @default.
• W2080943490 cites W1973091654 @default.
• W2080943490 cites W1976401925 @default.
• W2080943490 cites W1998258610 @default.
• W2080943490 cites W1999752605 @default.
• W2080943490 cites W2018604730 @default.
• W2080943490 cites W2020830322 @default.
• W2080943490 cites W2026180995 @default.
• W2080943490 cites W2030574136 @default.
• W2080943490 cites W2032490740 @default.
• W2080943490 cites W2055372756 @default.
• W2080943490 cites W2067757218 @default.
• W2080943490 cites W2069208866 @default.
• W2080943490 cites W2071244674 @default.
• W2080943490 cites W2078760290 @default.
• W2080943490 cites W2080823856 @default.
• W2080943490 cites W2085195756 @default.
• W2080943490 cites W2085550487 @default.
• W2080943490 cites W2086408819 @default.
• W2080943490 cites W2099237441 @default.
• W2080943490 cites W2100745065 @default.
• W2080943490 cites W2106067112 @default.
• W2080943490 cites W2107884772 @default.
• W2080943490 cites W2108592152 @default.
• W2080943490 cites W2110530327 @default.
• W2080943490 cites W2126844355 @default.
• W2080943490 cites W2128305064 @default.
• W2080943490 cites W2132108367 @default.
• W2080943490 cites W2135882644 @default.
• W2080943490 cites W2137074525 @default.
• W2080943490 cites W2138733343 @default.
• W2080943490 cites W2139248078 @default.
• W2080943490 cites W2140419616 @default.
• W2080943490 cites W2142168740 @default.
• W2080943490 cites W2144277728 @default.
• W2080943490 cites W2144517053 @default.
• W2080943490 cites W2147239532 @default.
• W2080943490 cites W2148360952 @default.
• W2080943490 cites W2150057437 @default.
• W2080943490 cites W2150678612 @default.
• W2080943490 cites W2156266214 @default.
• W2080943490 doi "https://doi.org/10.1002/ijc.24597" @default.
• W2080943490 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19621448" @default.
• W2080943490 hasPublicationYear "2009" @default.
• W2080943490 type Work @default.
• W2080943490 sameAs 2080943490 @default.
• W2080943490 citedByCount "119" @default.
• W2080943490 countsByYear W20809434902012 @default.
• W2080943490 countsByYear W20809434902013 @default.
• W2080943490 countsByYear W20809434902014 @default.
• W2080943490 countsByYear W20809434902015 @default.
• W2080943490 countsByYear W20809434902016 @default.
• W2080943490 countsByYear W20809434902017 @default.
• W2080943490 countsByYear W20809434902018 @default.
• W2080943490 countsByYear W20809434902019 @default.
• W2080943490 countsByYear W20809434902020 @default.
• W2080943490 countsByYear W20809434902021 @default.
• W2080943490 countsByYear W20809434902022 @default.
• W2080943490 countsByYear W20809434902023 @default.
• W2080943490 crossrefType "journal-article" @default.
• W2080943490 hasAuthorship W2080943490A5004316854 @default.
• W2080943490 hasAuthorship W2080943490A5009928901 @default.
• W2080943490 hasAuthorship W2080943490A5012460959 @default.
• W2080943490 hasAuthorship W2080943490A5015085014 @default.
• W2080943490 hasAuthorship W2080943490A5018392015 @default.
• W2080943490 hasAuthorship W2080943490A5020466822 @default.
• W2080943490 hasAuthorship W2080943490A5021731198 @default.
• W2080943490 hasAuthorship W2080943490A5023772387 @default.
• W2080943490 hasAuthorship W2080943490A5029794143 @default.
• W2080943490 hasAuthorship W2080943490A5036607864 @default.

• next